Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EDDC 2214

X
Drug Profile

EDDC 2214

Alternative Names: EDDC-2214; ETC-2162214

Latest Information Update: 18 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Experimental Drug Development Centre
  • Class Antivirals; Peptidomimetics
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued COVID 2019 infections

Most Recent Events

  • 18 Aug 2023 Discontinued - Preclinical for COVID-2019 infections in Singapore (PO)
  • 01 Jan 2023 Everest Medicines issues a termination notice to Experimental Drug Development Centre (EDDC), pursuant to which Everest desired to terminate the licensing agreement with EDDC and transfer the materials, reports and documents related to COVID-19 oral antiviral treatments to EDDC with no consideration
  • 01 Jan 2023 Everest Medicines terminates the licensing agreement with Experimental Drug Development Centre (EDDC) for COVID-19 oral antiviral treatments
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top